Virtus LifeSci Biotech Clinical Trials ETF
11 hedge funds and large institutions have $8.37M invested in Virtus LifeSci Biotech Clinical Trials ETF in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Holders
11
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$755K | |
| 2 | +$176K | |
| 3 | +$139K | |
| 4 |
Morgan Stanley
New York
|
+$35.2K |
Top Sellers
| 1 | -$411K | |
| 2 | -$317K | |
| 3 | -$43.2K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$27.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$17K |